Endophthalmitis after anti-VEGF injections

Ophthalmology. 2009 Jun;116(6):1225.e1. doi: 10.1016/j.ophtha.2009.02.031.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide / adverse effects
  • Bevacizumab
  • Cohort Studies
  • Drug Therapy, Combination
  • Endophthalmitis / diagnosis
  • Endophthalmitis / drug therapy
  • Endophthalmitis / etiology*
  • Humans
  • Injections
  • Macular Degeneration / drug therapy
  • Ranibizumab
  • Risk Factors
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide
  • Vascular Endothelial Growth Factor A
  • pegaptanib
  • Bevacizumab
  • Ranibizumab